Show simple item record

dc.contributor.authorDong, Lan-fengen_US
dc.contributor.authorJ.A. Jameson, Victoriaen_US
dc.contributor.authorTilly, Daviden_US
dc.contributor.authorProchazka, Lubomiren_US
dc.contributor.authorRohlena, Jakuben_US
dc.contributor.authorValis, Karelen_US
dc.contributor.authorTruksa, Jaroslaven_US
dc.contributor.authorZobalova, Renataen_US
dc.contributor.authorMahdavian, Elaheen_US
dc.contributor.authorKluckova, Katarinaen_US
dc.contributor.authorStantic, Marinaen_US
dc.contributor.authorStursa, Janen_US
dc.contributor.authorLambrechts, Ruthen_US
dc.contributor.authorK. Witting, Paulen_US
dc.contributor.authorNorberg, Eriken_US
dc.contributor.authorGoodwin, Jacoben_US
dc.contributor.authorA. Salvatore, Brianen_US
dc.contributor.authorNovotna, Janaen_US
dc.contributor.authorTuranek, Jaroslaven_US
dc.contributor.authorLedvina, Miroslaven_US
dc.contributor.authorHozak, Pavelen_US
dc.contributor.authorZhivotovsky, Borisen_US
dc.contributor.authorCoster, Marken_US
dc.contributor.authorRalph, Stephenen_US
dc.contributor.authorA.J. Smith, Robinen_US
dc.contributor.authorNeuzil, Jirien_US
dc.date.accessioned2017-04-24T11:56:56Z
dc.date.available2017-04-24T11:56:56Z
dc.date.issued2011en_US
dc.date.modified2012-03-01T22:15:37Z
dc.identifier.issn08915849en_US
dc.identifier.doi10.1016/j.freeradbiomed.2011.02.032en_US
dc.identifier.urihttp://hdl.handle.net/10072/43236
dc.description.abstractMitochondria are emerging as intriguing targets for anti-cancer agents. We tested here a novel approach, whereby the mitochondrially targeted delivery of anti-cancer drugs is enhanced by the addition of a triphenylphosphonium group (TPP+). A mitochondrially targeted analog of vitamin E succinate (MitoVES), modified by tagging the parental compound with TPP+, induced considerably more robust apoptosis in cancer cells with a 1-2 log gain in anti-cancer activity compared to the unmodified counterpart, while maintaining selectivity for malignant cells. This is because MitoVES associates with mitochondria and causes fast generation of reactive oxygen species that then trigger mitochondria-dependent apoptosis, involving transcriptional modulation of the Bcl-2 family proteins. MitoVES proved superior in suppression of experimental tumors compared to the untargeted analog. We propose that mitochondrially targeted delivery of anti-cancer agents offers a new paradigm for increasing the efficacy of compounds with anti-cancer activity.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.publisherElsevieren_US
dc.publisher.placeUnited Statesen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom1546en_US
dc.relation.ispartofpageto1555en_US
dc.relation.ispartofissue11en_US
dc.relation.ispartofjournalFree Radical Biology & Medicineen_US
dc.relation.ispartofvolume50en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchBiochemistry and Cell Biology not elsewhere classifieden_US
dc.subject.fieldofresearchcode060199en_US
dc.titleMitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapyen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Medical Scienceen_US
gro.date.issued2011
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record